News Heart drug biotech Kardigan raises $400m in upscaled IPO Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.
News Heart drug developer Kardigan files IPO The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
